Macrofungi production and economic value have been increasing globally. The demand for macrofungi has expanded rapidly owing to their popularity among consumers, pleasant taste, and unique flavors. The presence of high quality proteins, polysaccharides, unsaturated fatty acids, minerals, triterpene sterols, and secondary metabolites makes macrofungi an important commodity. Macrofungi are well known for their ability to protect from or cure various health problems, such as immunodeficiency, cancer, inflammation, hypertension, hyperlipidemia, hypercholesterolemia, and obesity. Many studies have demonstrated their medicinal properties, supported by both in vivo and in vitro experimental studies, as well as clinical trials. Numerous bioactive compounds isolated from mushrooms, such as polysaccharides, proteins, fats, phenolic compounds, and vitamins, possess strong bioactivities. Consequently, they can be considered as an important source of nutraceuticals. Numerous edible mushrooms have been studied for their bioactivities, but only a few species have made it to the market. Many species remain to be explored. The converging trends and popularity of eastern herbal medicines, natural/organic food product preference, gut-healthy products, and positive outlook towards sports nutrition are supporting the growth in the medicinal mushroom market. The consumption of medicinal mushrooms as functional food or dietary supplement is expected to markedly increase in the future. The global medicinal mushroom market size is projected to increase by USD 13.88 billion from 2018 to 2022. The global market values of promising bioactive compounds, such as lentinan and lovastatin, are also expected to rise. With such a market growth, mushroom nutraceuticals hold to be very promising in the years to come.

The oudemansielloid/xeruloid taxa Hymenopellis, Mucidula, Oudemansiella, and Xerula are genera of Basidiomycota that constitute an important resource of bioactive compounds. Numerous studies have shown antimicrobial, anti-oxidative, anti-cancer, anti-inflammatory and other bioactivities of their extracts. The bioactive principles can be divided into two major groups: (a) hydrophilic polysaccharides with relatively high molecular weights and (b) low molecular medium polar secondary metabolites, such as the antifungal strobilurins. In this review, we summarize the state of the art on biodiversity, cultivation of the fungi and bioactivities of their secondary metabolites and discuss future applications. Although the strobilurins are well-documented, with commercial applications as agrochemical fungicides, there are also other known compounds from this group that have not yet been well-studied. Polysaccharides, dihydro-citrinone phenol A acid, scalusamides, and acetylenic lactones such as xerulin, also have potential applications in the nutraceutical, pharmaceutical and medicinal market and should be further explored. Further studies are recommended to isolate high quality bioactive compounds and fully understand their modes of action. Given that only few species of oudemansielloid/xeruloid mushrooms have been explored for their production of secondary metabolites, these taxa represent unexplored sources of potentially useful and novel bioactive metabolites.

Hymenopellis is the most diverse genus in the group of oudemansielloid/xeruloid taxa (Physalacriaceae). This genus has a worldwide distribution with records mostly from Europe and America. Asian taxa are least represented. In this paper on Hymenopellis from Thailand, two novel species are introduced, and a Hymenopellis collection affine to H. orientalis is described. Macro and micromorphological characters are described. Maximum likelihood and Bayesian phylogenetic analyses were performed on combined ITS and nrLSU regions to confirm taxonomical placement and infer the phylogenetic affinities of the studied species. Hymenopellis straminea sp. nov. is straw-yellow, with medium-sized basidiomata, abundant and diverse in form cheilocystidia, few, narrowly lageniform to fusiform pleurocystidia, and clamp connections at the lower part of the stipe. Hymenopellis utriformis sp. nov. has mostly utriform pleurocystidia and 2-spored basidia. In the inferred phylogenies, the new species from this study formed distinct clades well supported by bootstrap proportions and posterior probabilities. The studied specimen affine to H. orientalis produced 2-spored basidia whereas published descriptions of other specimens mention 4-spored basidia. Moreover, the genetic distance between ITS sequences of this specimen and that of a Hymenopellis orientalis specimen from GenBank was 1.30–2.57%. Therefore, the conspecificity of our specimen with H. orientalis is uncertain, and additional specimens are needed to fully confirm its identity.